ReviewBritish journal of pharmacology2006
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy.
Review in British journal of pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients.The Cochrane database of systematic reviews · 2016Pooled it
- Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.The Cochrane database of systematic reviews · 2014Pooled it
- In vitro antiviral efficacy of amenamevir against feline herpesvirus 1.The Journal of veterinary medical science · 2025Article
- A Pharmacological Update of Oxadiazole Derivatives: A Review.Current topics in medicinal chemistry · 2025Review
- Probenecid Inhibits Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase Mitogen-Activated Protein Kinase Pathways in Regulating Respiratory Syncytial Virus Response.International journal of molecular sciences · 2024Article
- In Vitro Profiling of the Antiviral Peptide TAT-I24.International journal of molecular sciences · 2024Article
- Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.Journal of medicinal chemistry · 2024Article
- Review
- HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors.Virology journal · 2024Article
- Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives.Journal of clinical medicine · 2024Review
- The Overview of Potential Antiviral Bioactive Compounds in Poxviruses.Advances in experimental medicine and biology · 2024Review
- Perspective use of bio-adhesive liquid crystals as ophthalmic drug delivery systems.Scientific reports · 2023Article
- Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.Molecular diversity · 2023Article
- Anti-Zika Virus Activity and Isolation of Flavonoids from Ethanol Extracts ofMolecules (Basel, Switzerland) · 2023Article
- Top 100 Most-Cited Papers in Herpes Zoster from 2000 to 2022: A Bibliometric Study.Journal of pain research · 2023Article
- Replicative bypass studies of l-deoxyribonucleosides in Vitro and in E. coli cell.Scientific reports · 2022Article
- Nucleosides and emerging viruses: A new story.Drug discovery today · 2022Review
- Pharmacokinetics and analytical determination of acyclovir in Asian elephant calves (Veterinary and animal science · 2022Article
- Review
- Glyceroglycolipids in marine algae: A review of their pharmacological activity.Frontiers in pharmacology · 2022Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the discovery of the first effective antiviral compound (idoxuridine) in 1959, nucleoside analogues, especially acyclovir (ACV) for the treatment of herpesvirus infections, have dominated antiviral therapy for several decades. However, ACV and similar acyclic nucleosides suffer from low aqueous solubility and low bioavailability following oral administration. Derivatives of acyclic nucleosides, typically esters, were developed to overcome this problem and valaciclovir, the valine ester of ACV, was among the first of a new series of compounds that were readily metabolized upon oral administration to produce the antiviral nucleoside in vivo, thus increasing the bioavailility by several fold. Concurrently, famciclovir was developed as an oral formulation of penciclovir. These antiviral 'prodrugs' thus established a principle that has led to many successful drugs including both nucleoside and nucleotide analogues for the control of several virus infections, notably those caused by herpes-, retro- and hepatitisviruses. This review will chart the origins and development of the most important of the antiviral prodrugs to date.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.